A genetic contribution to develop chronic obstructive pulmonary disease (COPD) is well established. However, the specific genes responsible for enhanced risk or host differences in susceptibility to smoke exposure remain poorly understood. The goal of this review is to provide a comprehensive literature overview on the genetics of COPD, highlight the most promising findings during the last few years, and ultimately provide an updated COPD gene list. Candidate gene studies on COPD and related phenotypes indexed in PubMed before January 5, 2012 are tabulated. An exhaustive list of publications for any given gene was looked for. This well-documented COPD candidate-gene list is expected to serve many purposes for future replication studies and meta-analyses as well as for reanalyzing collected genomic data in the field. In addition, this review summarizes recent genetic loci identified by genome-wide association studies on COPD, lung function, and related complications. Assembling resources, integrative genomic approaches, and large sample sizes of well-phenotyped subjects is part of the path forward to elucidate the genetic basis of this debilitating disease.
Introduction
Chronic obstructive pulmonary disease (COPD) is the third-leading cause of worldwide mortality and is predicted to remain a major public health problem in the near future. 1, 2 It is characterized by airflow limitations that occur in approximately 10% of adults aged $ 40 years. 3 Cigarette smoking is the primary risk factor. However, only a fraction of smokers (∼20%) develop the disease, and host differences in susceptibility are thus persuasive. The author has previously reviewed the genetics of COPD and COPD-related phenotypes. 4 The current review aims to: (1) update this publication, (2) provide a comprehensive literature overview on the genetics of COPD, (3) highlight the most promising findings during the last few years, and ultimately (4) provide an updated COPD gene list.
Chronic obstructive pulmonary disease candidate-gene studies
A systematic review of the literature was conducted in order to provide a comprehensive overview of genes associated with COPD and related phenotypes. PubMed was searched using the string "genetics and COPD" on January 5, 2012. All titles and abstracts were reviewed for inclusion. The goal was to obtain all publications testing genetic variants in humans for association with COPD and related phenotypes (ie, spirometric measurements, emphysema, chronic bronchitis, lungfunction decline, etc). Population-based, case-control, and family studies were included. The author attempted to include all reported articles without quality assessment or exclusion criteria based on sample size or other criteria. The search for relevant publications was complemented using the list of references in relevant manuscripts and the COPD genetic association compendium. 5 Readers are welcome to contact the author for any articles missed in the current review.
A large number of candidate gene-association studies were conducted to identify the COPD-susceptibility genes. Table 1 provides a comprehensive overview of the genes associated with COPD and related phenotypes using this genetic approach. Supplementary Table 1 presents additional genes tested but showing lack of association with COPD and related phenotypes. Most genes in these tables were studied because of their potential role in the pathobiology of COPD, but some also represent follow-up genes originally identified from genome-wide linkage and association studies. Genes are presented in alphabetical order. Single studies and metaanalyses testing each gene are indicated. An attempt was made to classify each article as supportive or not of a given gene based on the conclusions provided by the authors. Single genetic markers, haplotypes, or combinations of variants associated with COPD, COPD severity, COPD-related phenotypes, or complications were considered as positives. Table 1 aims to provide an exhaustive list of publications for any given gene.
A total of 192 genes are summarized in Table 1 and Supplementary Table 1. Figure 1 illustrates these genes based on the number of publications supporting the association with COPD phenotypes. Briefly, 86 genes are supported by one study, 36 genes by two to five studies, 15 genes by six to ten studies, and seven genes by more than ten studies. The latter seven genes include ADRB2, TGFB1, TNF, GSTM1, GSTP1, SERPINA1, and EPHX1. Note that Figure 1 must be interpreted with caution. Replication of genotype-phenotype associations is the gold standard to identify genes conferring susceptibility. 6 However, the number of supportive studies is not necessarily an indication that a gene is consistently replicated. Figure 2 illustrates the relationship between the number of studies supporting and not supporting the list of COPD genes. It seems that genes replicated many times in COPD are simply the most popular genes studied. For example, the author found 20 studies supporting TNF as a COPDsusceptibility gene. However, lack of association between this gene and COPD phenotypes was found in 20 other studies (Table 1) . Considering publication bias, candidate genes associated with COPD are not consistently replicated and the overall results are rather inconclusive. In fact, excluding SERPINA1 (encoding the alpha-1 antitrypsin protein), none of the other genes are well-proven susceptibility genes for COPD. Perhaps the most convincing candidate COPD genes up to now are those less studied but consistently replicated, such as SOD3. Many of the most studied COPD genes have now been investigated in meta-analyses.
Meta-analyses
A number of meta-analyses have been conducted to identify genes robustly associated with COPD and lung function. So far, meta-analyses have been conducted for genes involved in the following pathways: inflammation (IL4, IL6, IL13, IL1B, IL1RN, LTA, TNF, and TGFB1), protease/antiprotease (MMP9, TIMP2, and SERPINA3), oxidative stress (GSTM1, GSTP1, GSTT1, EPHX1, SOD2, and SOD3), and others (ACE and ADRB2). These studies and their main outcomes are summarized by gene in Table 1 . Among these genes, GSTM1 was consistently associated with COPD in more than one meta-analysis. 5, 7, 8 This is also true for TNF, but only in Asian populations. 5, [8] [9] [10] [11] In contrast, other genes have not been supported in meta-analyses conducted so far, including GSTT1, 5, 7, 8 IL1B, 5, 8 IL6, 5, 8 and MMP9. 5, 8 The other genes considered in meta-analyses were either reported in only one study or showed conflicting results across studies ( Table 1) .
As genetic data accumulates, more genes and polymorphisms will be considered in meta-analyses. Combining the findings of an increasing number of studies will allow pooled analyses in more homogenous subgroups based on ethnicity, smoking history, emphysema vs airway type of COPD, and others. These subgroup analyses are likely to be important in finding susceptibility genes for COPD. Ongoing activities gathering genetic data in the field of COPD are important. For example, a web application summarizing candidate-gene studies was recently established. 5 At the time of publication, this database included 108 genetic-association studies, including population-based and case-control studies but excluding family-based studies. Seventy-two genes were studied, focusing strictly on single-marker biallelic polymorphisms. A total of 27 genetic variants were found to be reported in three or more independent study populations and summarized into a meta-analysis. Four genes were found to carry a single genetic variant significantly associated with COPD, being GSTM1, TGFB1, TNF, and SOD3. It should be noted that this COPD genetic-association compendium has not been updated since April 2010 and does not included ORMDL3  PTGES3  RARRES2  SCGB1A1  SOD1  TBX21  THSD4  TLR2  TLR6  TLFRSF1A  TLFRSF1B ADRB2 (12) SERPINA1 (19) TGFB1 (13) TNF (20) GSTM1 (16) EPHX1 (25) GSTP1 (16) ACE (6) ADAM33 (6) IL1B (6) IL6 (6) CFTR (7) HMOX1 (7) IL10 (7) SERPINA3 (7) AQP5 (2) CD14 (2) TP53 (2) ABCC1 (3) CTLA4 (2) EDN1 (3) HHIP (3) IFNG (3) IL4 (3) MMP1 (3) SFTPD (3) SOD2 (3) TIMP2 (3) VDR (3) CYPIA1 (4) IL1RN (4) MMP12 (4) NOS3 (4) 15q24/25 (5) LTA (5) CYP1A2 (2) CYP2E1 (2) DEFB1 (2) ELN (2) HLA (2) IL4R (2) IREB2 (2) LTBP4 (2) MBL2 (2) MSR1 (2) NFE2LS (2) PLAUR (2) PTGS2 (2) SFTPA1 (2) TBXA2R (2) TLR4 (2) SFTPB (7) SOD3 (7) GC (8) MMP9 (8) SERPINE2 (8) GSTT1 (9) IL13 (9) A2M ALOX5AP BCL2 References are provided in Table 1 for genes supported by at least one publication and in Supplementary Table 1 for genes tested but not supported.
more recent genetic studies on COPD. Updating this type of resource is important to draw reliable conclusions about the contribution of genes. The number of studies for most COPD-susceptibility genes is currently insufficient to reach firm conclusions.
Multi-gene-association studies
A systematic replication study of genes associated with lung function was recently conducted in the SpiroMeta Consortium. 12 A literature search identified 104 publications reporting a positive association with lung-function traits in the general populations of diverse origins or in cohorts of patients with respiratory diseases. A total of 130 genes and 48 intergenic regions were studied in 20,288 individuals. Among the 16,936 genotyped or imputed single-nucleotide polymorphisms (SNPs) in these loci, none was significantly associated with forced expiratory volume in one second (FEV 1 ) or FEV 1 /forced vital capacity (FVC) ratio after correction for multiple testing. The strongest genetic association signals with FEV 1 were observed in ever-smokers in the SERPINA1 and PDE4D genes.
Smaller-scale studies testing multiple genes were also conducted in China. First, 170 asthmatic cases and 347 controls were evaluated for 119 SNPs in 98 genes for association with lung function. 13 After correction for multiple testing, none of the SNPs was significantly associated with lung function (ie, FEV 1 , FVC, or FEV 1 /FVC). The strongest association was observed between rs320995 (Phe309Phe) in CYSLTR1 and FEV 1 /FVC (P = 0.0004). Second, 1,261 SNPs in 380 candidate genes for cancer or other human diseases were tested for association with COPD in 53 cases and 107 controls with in-home coal exposure. 14 A total of 22 genes were associated with COPD risk, but only PTEN was significant after correction for multiple testing. Considering the small sample sizes, the results of these studies must be replicated before reaching firm conclusions. Table 2 summarizes COPD susceptibility loci identified by genome-wide association (GWA) studies. The results of the first GWA study on COPD were published in 2009. 15 The GWA study was conducted in a case-control cohort of submit your manuscript | www.dovepress.com
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Norway (823 COPD cases and 810 controls), and the top 100 SNPs were followed up in the family-based International COPD Genetics Network (ICGN). Two susceptibility loci were identified. The most definitive evidence of association was found with two SNPs at the α-nicotinic acetylcholine receptor locus on chromosome 15q25, the same locus implicated in the risk of lung cancer. [16] [17] [18] Two SNPs at the hedgehog interacting protein (HHIP) locus on chromosome 4q31 also showed strong associations.
The case-control cohort of Norway was then combined with the COPD cases from the National Emphysema Treatment Trial (NETT) and unaffected individuals from the Normative Aging Study (NAS), as well as cases and controls from the multicenter Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study. 19 A total of 2940 cases and 1380 controls were considered. Loci 15q25-CHRNA3/CHRNA5/IREB2 and 4q31-HHIP were replicated in this study. A third locus was also identified at 4q22.1 harboring the FAM13A gene. The latter was followed up and validated in the COPDGene study and the ICGN. A trend was also observed in the Boston Early-Onset COPD Study (EOCOPD). The latest GWA study on COPD was performed using 3499 cases and 1922 controls regrouping the ECLIPSE, NETT-NAS, Norway, and COPDGene studies. 20 The three GWA-nominated COPD-susceptibility loci (ie, CHRNA3/CHRNA5/IREB2, HHIP, and FAM13A) were confirmed in this extended GWA study. In addition, a new COPD locus was identified on chromosome 19q13, which harbored the RAB4B, EGLN2, MIA, and CYP2A6 genes. It was estimated that the four GWA-nominated COPD loci accounted for ∼5% of the total variance of the sibling relative risk of COPD. 20 Two of the four genome-wide associated loci found in COPD -15q25 and 19q13 -were previously associated with cigarettes smoked per day and cotinine levels, [21] [22] [23] [24] [25] suggesting that the risk alleles are acting through smoking behavior. Further studies support this hypothesis on 15q25. In fact, previous studies suggested that sequence variants on chromosome 15q25 confer risk of smoking-related lung diseases (ie, COPD and lung cancer) through its effect on tobacco addiction. 17, 26 This is consistent with the lack of association between the 15q25 locus and lung cancer among never-smokers. [27] [28] [29] In contrast, other evidence argues against this hypothesis, showing weak or no evidence that the 15q25 locus directly influences smoking behavior, 15, 16 no appreciable variation in the risk of lung cancer across smoking categories, 18 and significant effect of the 15q25 locus on smoking-related diseases after adjustment for smoking exposure. 30, 31 Multiple distinct loci affecting both smoking behavior 24, 31 and lung cancer 32 were reported on 15q25. It is still unknown whether genes located at any of these loci are causally involved in the pathogenesis of COPD and lung cancer or the effect is mediated by changing smoking behavior. Risk alleles on chromosome 15q25 were shown to modulate the mRNA expression levels of the CHRNA5 gene in the brain 33, 34 and lung 35 tissues as well as the expression of CHRNA5 and IREB2 genes in sputum. 36 The regulation of genes in primary disease tissues, such as lung and sputum, suggests a direct effect of 15q25 genes on COPD susceptibility. More functional studies are needed to find the causal alleles and genes on 15q25 as well as to disentangle their impact on correlated traits associated with this chromosomal region.
GWA studies on lung function
In 2007, Wilk et al 37 reported the first GWA study on lung function in approximately 1200 individuals. The study was conducted as part of the Framingham Heart Study. Association tests were performed on 70,987 autosomal SNPs and for ten spirometry phenotypes. No SNP was associated with lung-function phenotypes using stringent criteria for genome-wide significance, but suggestive evidence of association was provided for a nonsynonymous coding SNP in exon 5 of the GSTO2 gene. In 2009, a larger GWA study from the Framingham Heart Study was performed in 7691 participants. 38 Interestingly, the 4q31-HHIP COPD locus (INTS12, GSTCD, and NPNT) on 4q24 was identified. 4q24 (GSTCD), 5q33 (HTR4) and 6p21 (AGER) were common in both consortia, ie, SpiroMeta and CHARGE. The previously reported 4q31 locus located upstream of the HHIP gene associated with FEV 1 and FEV 1 / FVC ratio was also confirmed in these consortia.
More recently, a larger GWA study of FEV 1 and FEV 1 /FVC ratio was reported, comprising more than 48,000 individuals of European ancestry and followed up for replication in more than 46,000 individuals. 41 Ten out of eleven loci previously reported by the SpiroMeta and CHARGE consortia were replicated in this extended GWA study. Only PID1 on 2q36 was not replicated. More interestingly, 16 new loci were identified, including twelve loci for FEV 1 /FVC, three for FEV 1 , and one for both traits. Thus, 26 loci were associated with lung function in this GWA study. Together, these loci explain 3.2% of the additive polygenic variance for FEV 1 / FVC and 1.5% of the variance for FEV 1 .
The first GWA study on lung-function decline was recently reported. 42 Briefly, genome-wide analyses on FEV 1 and FEV 1 /FVC decline were conducted in 2677 nonasthmatics and 1441 asthmatics separately. The top hits were then replicated in 10,858 nonasthmatic and 1138 asthmatic participants. Decline of FEV 1 and FEV 1 /FVC ratio was evaluated during a follow-up examination period of roughly 10 years in these participants. No SNP reached genome-wide significance in the discovery set. However, one locus on chromosome 13q14.3 containing the DLEU7 gene was strongly associated with FEV 1 decline in nonasthmatics from the discovery set and confirmed in the replication set. A strong association signal was also reported on 8p22 harboring the TUSC3 gene for FEV 1 /FVC decrease in asthmatics, but not validated in the replication set. Many loci previously associated with cross-sectional lung function in GWA studies described above were replicated with baseline lung function in either asthmatic or nonasthmatic subjects. However, few GWAS-nominated lung-function loci were associated with lung-function decline, suggesting different genetic mechanisms governing baseline lung function and decline with age. In addition, this study showed the genetic heterogeneity of lung-function decline between subjects with and without asthma. Table 2 summarizes lung-function susceptibility loci identified by GWA studies.
GWA studies on COPD-related phenotypes
Other GWA studies were reported on COPD-related phenotypes. Emphysema is an important feature of COPD and varies considerably between patients. A recent GWA study was performed on emphysema measures by computed tomography scan and defined by radiologist qualitative scores and quantitative assessments of low-attenuation areas. 43 The qualitative scores obtained in 1557 patients from the ECLIPSE study and 432 subjects from the Norway cohort led to the identification of an emphysema locus on chromosome 12p11.2. The most strongly associated SNP is located in the BICD1 gene, known to be involved in regulating telomere length. The ECLIPSE, Norway, and NETT studies were also used to perform a GWA study on COPD-related cachexia phenotypes, including body mass index and fat-free mass index. 44 Cachexia occurs in approximately 10% of patients with COPD and is associated with increased mortality. The GWA study on body mass index and fat-free mass index in patients with COPD identified a single susceptibility locus that harbored the FTO gene, the most robust gene associated with obesity. Whether FTO acts through obesity or directly affects lung function remains to be elucidated.
GWA studies on COPD, lung function, and related phenotypes provided strong and consistent evidence of genetic susceptibility loci. These studies also highlight the large number of participants required to identify reproducible genetic loci. So far, GWA studies have identified only a small fraction of the genetic variants contributing to COPD risk, related complications, and lung-function variability. GWA studies on larger sample sizes, especially for COPD, will be required to identify the genetic factors underpinning COPD and related phenotypes. Large international efforts are under way to increase sample sizes and use more comprehensive molecular phenotyping (eg, gene expression in the lung) to elucidate the genetic component of COPD. 45, 46 It should be emphasized that the causal genes and genetic variants of all these newly discovered loci by GWA studies remain to be identified. More integrative genomic approaches will be required for these purposes. Different study designs testing rare and copy-number variants as well as gene-smoking interaction are also needed.
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Integrative genomic approaches
More studies are being conducted using integrative genomic approaches in order to identify COPD susceptibility genes. For example, the IREB2 gene was identified by combining gene expression in human lungs and genetic association in COPD cohorts. 47 In this study, lung specimens were obtained from patients undergoing lung nodule resection, and gene expression was compared between 15 COPD and 18 non-COPD patients using whole-genome gene-expression arrays. A total of 889 SNPs found in the 62 genomic regions containing genes differentially expressed between patients with or without COPD were tested for association with COPD and lung function. Seventy-one SNPs nominally associated (P # 0.05) with COPD in the NETT-NAS study were followed up for replication in the EOCOPD study. A gene-based replication was then completed to confirm genetic association between genetic variants in the IREB2 gene and lung function. Overall, the IREB2 gene was shown to be upregulated in lung specimens of COPD patients and to contain genetic variants associated with COPD. Gene expression in a larger number of lung specimens will be required to test whether COPD-associated SNPs in the IREB2 gene influence the expression of its gene product.
Although Table 2 shows the major susceptibility loci identified by GWA studies, many additional loci were borderline significant in these studies. Many true positives are likely to be missed by this approach owing to the stringent threshold used to control for false-discovery rates. Different weighting methods and SNP-prioritization strategies are currently used to find true-positive signals from previous GWA studies. For example, the FGF7 gene was recently identified as a COPD susceptibility locus by weighting GWA analysis on regions of conserved homozygosity haplotype in subjects affected with COPD compared to unaffected subjects. 48 As mentioned previously, 49 further studies reanalyzing genome-wide SNP datasets with weighting methods based on function annotations (eg, coding variants or regions) or prior knowledge (eg, candidate genes or genomewide linkage studies) will be required. Similarly, ongoing lung expression quantitative trait loci (eQTLs) mapping data 36,46 are likely to leverage the impact of previous GWA studies on COPD by providing a list of SNPs that regulate gene expression in relevant tissues. SNPs associated with gene expression will provide crucial functional information to understand the molecular changes introduced by the susceptibility DNA variants. The identification of SNPs associated with both disease traits and quantitative transcript levels of one or more genes in relevant tissues will highlight the most likely causal gene within the susceptibility loci and the functional SNPs that are prime candidates to be directly involved in the pathogenesis of COPD.
Conclusion
Elucidating the genetic component of COPD and lung function turned out to be a challenging task. Major resources and collaborative efforts will be required to achieve our goal. In this review, the author provides an updated list of COPD genes and a summary of GWAS results conducted during the last few years. It is hoped that the gene list can be used by investigators to replicate or refute susceptibility genes of COPD. As eluded above, this gene list can also be used to reanalyze GWA data by prioritizing genes previously associated with COPD or related phenotypes or enter into more global gene network and causality analyses. Owing to the challenge faced by the genetic community, large collections of patients well characterized for COPD phenotypes are ongoing to identify the genuine COPD genes. A lumping and splitting strategy is an old idea in the field of genetics of complex traits 50 that will certainly be essential in the field of COPD. Pooling resources (ie, lumping) is required to obtain proper sample sizes, but is likely to increase heterogeneity. These larger sample sizes, however, provide the opportunity to subdivide (ie, splitting) the pooled data into more homogeneous subgroups where the molecular defects are more likely to be similar. Accordingly, not only the genetic community but the entire spectrum of experts managing and treating patients with COPD will be required to provide samples, precise phenotypes, and expertise to search for the underlying genetic mechanisms. In parallel, complementary multidimensional genomic data in relevant tissues (eg, lung eQTLs) will be crucial to uncover causal genes and genetic variants that contribute to COPD and to discover new molecular targets for prevention, diagnosis, and treatment. 
